Altogether, the findings imply that MS13 may demonstrate its anti-cancer effects in U-87 MG and SH-SY5Y cells by downregulating GAPDH and ENO1, which disrupts the glycolytic pathway and subsequently results in the reduction of energy production and inhibition of cell proliferation. This evidence concerns the gene GAPDH and cancer.